Edwards Lifesciences Holds 2025 EPS Outlook Despite Tariff Headwind

Company Is Implementing Plans To Mitigate Cost Pressures

 
• By Shubham Singh
  
Singapore and Costa Rica account for about 70% to 80% of Edwards’ tariff exposure. (Shutterstock)

More from Strategy

More from Medtech Insight